AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
@article{Lewitt2011AAV2GADGT, title={AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial}, author={P. Lewitt and A. Rezai and M. Leehey and S. Ojemann and A. Feigin and S. Tatter}, journal={The Lancet Neurology}, year={2011}, volume={10}, pages={309-319} }
BACKGROUND
Gene transfer of glutamic acid decarboxylase (GAD) and other methods that modulate production of GABA in the subthalamic nucleus improve basal ganglia function in parkinsonism in animal models. We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease.
METHODS
Patients aged 30-75 years who had progressive levodopa-responsive Parkinson's disease and an overnight off-medication… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
The purpose of this study is to determine the safety and efficacy of AAV-GAD gene transfer
into the subthalamic nucleus (STN) region of the brain. This study involves the treatment of… Expand
Conditions | Parkinson's Disease |
---|---|
Intervention | Genetic |
Topics from this paper
Paper Mentions
507 Citations
Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.
- Medicine
- JCI insight
- 2017
- 32
Parkinson disease: Gene therapy for Parkinson disease shows promise in phase II trial
- Medicine
- Nature Reviews Neurology
- 2011
- 3
Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease
- Medicine
- Current neurology and neuroscience reports
- 2011
- 9
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
- Medicine
- The Lancet
- 2014
- 318
- PDF
Gene Therapy for Parkinson’s Disease: Preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis
- Medicine
- Molecular therapy. Methods & clinical development
- 2019
- 2
Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands
- Medicine
- Neurobiology of Disease
- 2017
- 32
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease
- Medicine
- Journal of Neurology, Neurosurgery, and Psychiatry
- 2020
- 1
- PDF
References
SHOWING 1-10 OF 35 REFERENCES
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- Medicine
- The Lancet Neurology
- 2010
- 389
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
- Medicine
- The Lancet
- 2007
- 907
- PDF
A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.
- Medicine
- Molecular therapy : the journal of the American Society of Gene Therapy
- 2010
- 177
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
- Medicine
- Neurology
- 2009
- 321
A randomized trial of deep-brain stimulation for Parkinson's disease.
- Medicine
- The New England journal of medicine
- 2006
- 2,080
- PDF
Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism
- Biology, Medicine
- Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
- 2007
- 117
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
- Medicine
- The Lancet Neurology
- 2008
- 478
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease
- Medicine
- Proceedings of the National Academy of Sciences
- 2007
- 169
- PDF
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
- Medicine
- The New England journal of medicine
- 2010
- 950
- PDF